

Toronto, Ontario, and Lyon, France;
April 15, 2008

Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global Health

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is investing 100 million Canadian dollars in a new, state-of-the-art research facility at the company's historic Connaught Campus in north Toronto, Ontario, Canada, to boost innovation in vaccine research for the benefit of global health. The investment includes the construction of an 80 million Canadian dollars facility, the purchase of specialized research & development (R&D) equipment, and the support of high-value R&D jobs over the next five years.

For this project, sanofi pasteur is pleased to partner with the Government of Ontario, which will contribute 13.9 million Canadian dollars through the Biopharmaceutical Investment Program (BIP). The BIP is administered by the Ministry of Research and Innovation and is part of the government's Next Generation of Jobs Fund.

"This new research in Ontario will not only create jobs, it will bring hope to people affected by disease," said Ontario Premier Dalton McGuinty.

Construction of the 165,000 square-foot (15,000 square-meter) facility will begin in 2008 and is projected to be ready for occupancy in 2010. This significant investment aims at accelerating sanofi pasteur's ongoing research activities based in Canada. With this announcement, sanofi pasteur has invested over 300 million Canadian dollars in capital expansion at its Connaught Campus located in Toronto since 2000.

"Today's announcement demonstrates sanofi pasteur's commitment to growing research and development capabilities in Canada for new and innovative vaccines that will help protect the health of people worldwide," said Wayne Pisano, President and Chief Executive Officer of sanofi pasteur. *"The Connaught Campus is already recognized globally for the research, development and manufacture of the five-component acellular pertussis vaccine. Global demand for new and existing vaccines is anticipated to double by the year 2016, reinforcing the importance of continued investment in research and development."*

Research conducted at the new facility will help support the company's global research and development efforts to improve existing vaccines and create new vaccines. Research targets will include pediatric combination vaccines, pneumococcal protein vaccines, and cancer vaccines. The new facility is part of an ongoing commitment to research and development in the area of immunology.



In addition to being a state-of-the art vaccine research and development facility, the new R&D facility will incorporate a number of new technologies to reduce environmental impact. A heat reclamation system will reduce heating and cooling requirements, the insulated building panels and glass structure will reduce energy consumption, and the building will be fitted with energy-efficient lighting. The facility's electrical and steam requirements will be serviced by the company's natural gas-powered cogeneration system.

Sanofi Pasteur has a tradition of more than 90-years of protecting and safeguarding the public health of Canadians. Along with innovation in acellular pertussis vaccines, sanofi pasteur also supplies the only conjugate vaccine in Canada that protects against four of the five strains of bacteria that cause meningococcal meningitis. Sanofi Pasteur invests approximately 100 million Canadian dollars in R&D annually in Canada.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a 1.6 billion doses of vaccine in 2007, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.ca

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2007. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Global Media Relations

Pascal Barollier
T. +33-(0)4-37-37-50-38
Pascal.barollier@sanofipasteur.com
www.sanofipasteur.com

Canada Media Relations

Nancy Simpson
T. +1 (416) 667-2955
nancy.simpson@sanofipasteur.com
www.sanofipasteur.ca